Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, usually aggressive primary thymic carcinoma, characterized by a syncytial growth of undifferentiated carcinoma cells and the presence of a lymphoplasmacytic infiltrate. More than 40% of cases are associated with Epstein-Barr virus infection.
Biomarker and diagnostic research for lymphoepithelioma-like thymic carcinoma has been reported in the published literature.
No clinical trials have been registered for lymphoepithelioma-like thymic carcinoma.
13 publications have been identified in PubMed for lymphoepithelioma-like thymic carcinoma. Research spans Review / Meta-Analysis (31%), Case Report / Case Series (31%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 | 31% |
Data assembled from 2 of 12 sources · Last updated Nov 4, 2026, 8:40 AM UTC
Patient case studies
4 |
31% |
Testing and diagnosis research | 2 | 15% |
Laboratory research | 2 | 15% |
Other research | 1 | 8% |
Agaimy A (2026). [PMID: 40913630](https://pubmed.ncbi.nlm.nih.gov/40913630/). *Virchows Arch*. [Basic Science / Preclinical]
Hu T (2025). [PMID: 40985516](https://pubmed.ncbi.nlm.nih.gov/40985516/). *Pediatr Blood Cancer*. [Other]
Teng H (2025). [PMID: 41093139](https://pubmed.ncbi.nlm.nih.gov/41093139/). *Lab Invest*. [Basic Science / Preclinical]
Zhang D (2025). [PMID: 40674896](https://pubmed.ncbi.nlm.nih.gov/40674896/). *Ann Diagn Pathol*. [Diagnostic / Biomarker]
Zhu XD (2025). [PMID: 40061425](https://pubmed.ncbi.nlm.nih.gov/40061425/). *Front Pediatr*. [Case Report / Case Series]
Suster DI (2025). [PMID: 38884541](https://pubmed.ncbi.nlm.nih.gov/38884541/). *Arch Pathol Lab Med*. [Diagnostic / Biomarker]
Thomas-de-Montpréville V (2025). [PMID: 38725394](https://pubmed.ncbi.nlm.nih.gov/38725394/). *Histol Histopathol*. [Review / Meta-Analysis]
Shan Y (2025). [PMID: 41339246](https://pubmed.ncbi.nlm.nih.gov/41339246/). *Arch Esp Urol*. [Case Report / Case Series]
Miura K (2025). [PMID: 40840890](https://pubmed.ncbi.nlm.nih.gov/40840890/). *Kyobu Geka*. [Case Report / Case Series]
He L (2025). [PMID: 40242968](https://pubmed.ncbi.nlm.nih.gov/40242968/). *Fetal Pediatr Pathol*. [Review / Meta-Analysis]
AI-curated news mentioning lymphoepithelioma-like thymic carcinoma
Updated Sep 23, 2026
Preliminary results from a phase II trial indicate that ivonescimab combined with chemotherapy may be an effective first-line treatment for advanced thymic carcinoma. The study also includes biomarker analyses that could inform future treatment strategies.
A case report details pulmonary sarcomatoid carcinoma in the anterior mediastinum that mimicked thymic carcinoma, highlighting its potential for rapid widespread metastases. This discovery may inform future diagnostic approaches and treatment strategies.
A nationwide analysis in Japan from 2018 to 2022 reveals treatment practices for advanced thymoma and advanced thymic carcinoma. This study provides insights into evolving therapeutic approaches for these rare tumors.